Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Alvotech (NASDAQ: ALVO, or the "Company”), a global biotech company specializing in the development and manufacture of ...

Total Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 millionProduct revenues in the first nine ...

The Committee for Medicinal Products for Human Use (CHMP ... The main issue for the company is that Amgen’s rival KRAS inhibitor Lumykras (sotorasib) has already been given conditional approval ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

and the drug could also have applications in additional respiratory and gastrointestinal indications, according to Blackstone. Solrikitug is in the same class as Amgen and AstraZeneca’s Tezspire ...

TEZSPIRE demonstrated a statistically significant and clinically meaningful reduction in nasal polyp size and reduced nasal congestion compared to placebo ...

Worldwide Healthcare Trust PLC - Half-year Report PR Newswire LONDON, United Kingdom, November 15 LONDON STOCK EXCHANGE ANNOUNCEMENTWorldwide Healthcare Trust PLCUnaudited ...

In particular, acute cannabis exposure in children can result in serious and potentially life-threatening consequences, including CNS depression, respiratory depression, coma, and in rare cases death.